HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, STX, VLG, and EAH
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), and ECO Animal Health Group (EAH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Hikma Pharmaceuticals vs. Its Competitors
Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.
In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for Hikma Pharmaceuticals. HUTCHMED's average media sentiment score of 0.99 beat Hikma Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.
Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of HUTCHMED shares are held by institutional investors. 17.8% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.
Hikma Pharmaceuticals presently has a consensus price target of GBX 2,627.50, indicating a potential upside of 48.20%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HIK) was last updated on 10/16/2025 by MarketBeat.com Staff
